RCT | Efficacy of RBX2660 for preventing recurrent Clostridioides difficile after antibiotic treatment.

Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection – Drugs

Commentary: RBX2660 shows promise in breaking the cycle of recurrent C. difficile – MDedge